Cardiff University

About: Cardiff University is a education organization based out in Cardiff, United Kingdom. It is known for research contribution in the topics: Population & Context (language use). The organization has 34188 authors who have published 82643 publications receiving 3046531 citations. The organization is also known as: University of Cardiff & University College of South Wales and Monmouthshire.

Herschel view of the Taurus B211/3 filament and striations: evidence of filamentary growth?

Abstract: We present first results from the Herschel Gould Belt survey for the B211/L1495 region in the Taurus molecular cloud. Thanks to their high sensitivity and dynamic range, the Herschel images reveal the structure of the dense, star-forming filament B211 with unprecedented detail, along with the presence of striations perpendicular to the filament and generally oriented along the magnetic field direction as traced by optical polarization vectors. Based on the column density and dust temperature maps derived from the Herschel data, we find that the radial density profile of the B211 filament approaches power-law behavior, ρ ∝ r−2.0± 0.4, at large radii and that the temperature profile exhibits a marked drop at small radii. The observed density and temperature profiles of the B211 filament are in good agreement with a theoretical model of a cylindrical filament undergoing gravitational contraction with a polytropic equation of state: P ∝ ργ and T ∝ ργ−1, with γ = 0.97 ± 0.01 < 1 (i.e., not strictly isothermal). The morphology of the column density map, where some of the perpendicular striations are apparently connected to the B211 filament, further suggests that the material may be accreting along the striations onto the main filament. The typical velocities expected for the infalling material in this picture are ~0.5–1 km s-1, which are consistent with the existing kinematical constraints from previous CO observations.

Uncertain climate: An investigation into public scepticism about anthropogenic climate change

Abstract: This study presents a detailed investigation of public scepticism about climate change in Britain using the trend, attribution, and impact scepticism framework of Rahmstorf (2004). The study found that climate scepticism is currently not widespread in Britain. Although uncertainty and scepticism about the potential impacts of climate change were fairly common, both trend and attribution scepticism were far less prevalent. It further showed that the different types of scepticism are strongly interrelated. Although this may suggest that the general public does not clearly distinguish between the different aspects of the climate debate, there is a clear gradation in prevalence along the Rahmstorf typology. Climate scepticism appeared particularly common among older individuals from lower socio-economic backgrounds who are politically conservative and hold traditional values; while it is less common among younger individuals from higher socio-economic backgrounds who hold self-transcendence and environmental values. The finding that climate scepticism is rooted in people's core values and worldviews may imply a coherent and encompassing sceptical outlook on climate change. However, attitudinal certainty appeared mainly concentrated in non-sceptical groups, suggesting that climate sceptical views are not held very firmly. Implications of the findings for climate change communication and engagement are discussed.

Declines of managed honey bees and beekeepers in Europe

Abstract: Growing evidence indicates that European managed honey bees are in decline, but information for Europe remains patchy and localized. Here we compile data from 18 European countries to assess trends in the number of honey bee colonies and beekeepers between 1965 and 2005. We found consistent declines in colony numbers in central European countries and some increases in Mediterranean countries. Beekeeper numbers have declined in all of the European countries examined. Our data support the view that honey bees are in decline at least in some regions, which is probably closely linked to the decreasing number of beekeepers. Our data on colony numbers and beekeepers must, however, be interpreted with caution due to different approaches and socioeconomic factors in the various countries, thereby limiting their comparability. We therefore make specific recommendations for standardized methodologies to be adopted at the national and global level to assist in the future monitoring of honey bees.

Association of Cardiometabolic Multimorbidity With Mortality

Abstract: IMPORTANCE: The prevalence of cardiometabolic multimorbidity is increasing. OBJECTIVE: To estimate reductions in life expectancy associated with cardiometabolic multimorbidity. DESIGN, SETTING, AND PARTICIPANTS: Age- and sex-adjusted mortality rates and hazard ratios (HRs) were calculated using individual participant data from the Emerging Risk Factors Collaboration (689,300 participants; 91 cohorts; years of baseline surveys: 1960-2007; latest mortality follow-up: April 2013; 128,843 deaths). The HRs from the Emerging Risk Factors Collaboration were compared with those from the UK Biobank (499,808 participants; years of baseline surveys: 2006-2010; latest mortality follow-up: November 2013; 7995 deaths). Cumulative survival was estimated by applying calculated age-specific HRs for mortality to contemporary US age-specific death rates. EXPOSURES: A history of 2 or more of the following: diabetes mellitus, stroke, myocardial infarction (MI). MAIN OUTCOMES AND MEASURES: All-cause mortality and estimated reductions in life expectancy. RESULTS: In participants in the Emerging Risk Factors Collaboration without a history of diabetes, stroke, or MI at baseline (reference group), the all-cause mortality rate adjusted to the age of 60 years was 6.8 per 1000 person-years. Mortality rates per 1000 person-years were 15.6 in participants with a history of diabetes, 16.1 in those with stroke, 16.8 in those with MI, 32.0 in those with both diabetes and MI, 32.5 in those with both diabetes and stroke, 32.8 in those with both stroke and MI, and 59.5 in those with diabetes, stroke, and MI. Compared with the reference group, the HRs for all-cause mortality were 1.9 (95% CI, 1.8-2.0) in participants with a history of diabetes, 2.1 (95% CI, 2.0-2.2) in those with stroke, 2.0 (95% CI, 1.9-2.2) in those with MI, 3.7 (95% CI, 3.3-4.1) in those with both diabetes and MI, 3.8 (95% CI, 3.5-4.2) in those with both diabetes and stroke, 3.5 (95% CI, 3.1-4.0) in those with both stroke and MI, and 6.9 (95% CI, 5.7-8.3) in those with diabetes, stroke, and MI. The HRs from the Emerging Risk Factors Collaboration were similar to those from the more recently recruited UK Biobank. The HRs were little changed after further adjustment for markers of established intermediate pathways (eg, levels of lipids and blood pressure) and lifestyle factors (eg, smoking, diet). At the age of 60 years, a history of any 2 of these conditions was associated with 12 years of reduced life expectancy and a history of all 3 of these conditions was associated with 15 years of reduced life expectancy. CONCLUSIONS AND RELEVANCE: Mortality associated with a history of diabetes, stroke, or MI was similar for each condition. Because any combination of these conditions was associated with multiplicative mortality risk, life expectancy was substantially lower in people with multimorbidity.

Donepezil and memantine for moderate-to-severe Alzheimer's disease.

Abstract: A b s t r ac t Background Clinical trials have shown the benefits of cholinesterase inhibitors for the treatment of mild-to-moderate Alzheimer’s disease. It is not known whether treatment benefits continue after the progression to moderate-to-severe disease. Methods We assigned 295 community-dwelling patients who had been treated with donepezil for at least 3 months and who had moderate or severe Alzheimer’s disease (a score of 5 to 13 on the Standardized Mini–Mental State Examination [SMMSE, on which scores range from 0 to 30, with higher scores indicating better cognitive function]) to continue donepezil, discontinue donepezil, discontinue donepezil and start memantine, or continue donepezil and start memantine. Patients received the study treatment for 52 weeks. The coprimary outcomes were scores on the SMMSE and on the Bristol Activities of Daily Living Scale (BADLS, on which scores range from 0 to 60, with higher scores indicating greater impairment). The minimum clinically important differences were 1.4 points on the SMMSE and 3.5 points on the BADLS. Results Patients assigned to continue donepezil, as compared with those assigned to discontinue donepezil, had a score on the SMMSE that was higher by an average of 1.9 points (95% confidence interval [CI], 1.3 to 2.5) and a score on the BADLS that was lower (indicating less impairment) by 3.0 points (95% CI, 1.8 to 4.3) (P<0.001 for both comparisons). Patients assigned to receive memantine, as compared with those assigned to receive memantine placebo, had a score on the SMMSE that was an average of 1.2 points higher (95% CI, 0.6 to 1.8; P<0.001) and a score on the BADLS that was 1.5 points lower (95% CI, 0.3 to 2.8; P = 0.02). The efficacy of donepezil and of memantine did not differ significantly in the presence or absence of the other. There were no significant benefits of the combination of donepezil and memantine over donepezil alone. Conclusions In patients with moderate or severe Alzheimer’s disease, continued treatment with donepezil was associated with cognitive benefits that exceeded the minimum clinically important difference and with significant functional benefits over the course of 12 months. (Funded by the U.K. Medical Research Council and the U.K. Alzheimer’s Society; Current Controlled Trials number, ISRCTN49545035.)